Biomea Fusion Inc

Biomea Fusion, Inc. is a biopharmaceutical company, which engages in the discovery, development, and commercialization of irreversible small molecules to treat patients with genetically defined cancers. The company was founded by Thomas Butler and Ramses Erdtmann in August 2017 and is headquartered in Redwood City, CA.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Biomea Fusion, Inc. is a biopharmaceutical company, which engages in the discovery, development, and commercialization of covalent small molecule drugs to treat patients with genetically defined cancers and metabolic disorders, such as diabetes. It offers its lead product candidate, BMF-219, an orally bioavailable, potent, and selective covalent inhibitor of menin, a transcriptional regulator known to play a direct role in oncogenic signaling in multiple cancers. The company was founded by Thomas Butler and Ramses Erdtmann in August 2017 and is headquartered in Redwood City, CA.

NEW YORK , July 1, 2024 /PRNewswire/ -- Rosen Law Firm, a global investor rights law firm, announces an investigation of potential securities claims on behalf of shareholders of Biomea Fusion, Inc. (NASDAQ: BMEA) resulting from allegations that Biomea Fusion may have issued materially misleading business information to the investing public. So what: If you purchased Biomea Fusion securities you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fee arrangement.

BMEA ANNOUNCEMENT: If You Have Suffered Losses in Biomea Fusion, Inc. (NASDAQ: BMEA), You Are Encouraged to Contact The Rosen Law Firm About Your Rights

LOS ANGELES, CA / ACCESSWIRE / July 1, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Biomea Fusion, Inc.. ("Biomea" or "the Company") (NASDAQ:BMEA) violations of the securities laws.

The Schall Law Firm Is Undertaking An Investigation Into Charges Against Biomea Fusion Inc And Encourages Shareholders With Losses To Reach Out

LOS ANGELES, CA / ACCESSWIRE / June 30, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Biomea Fusion, Inc.. ("Biomea" or "the Company") (NASDAQ:BMEA) violations of the securities laws.

The Schall Law Firm Is Launching An Examination Of Allegations Against Biomea Fusion Inc And Calls On Shareholders With Losses To Connect

LOS ANGELES, CA / ACCESSWIRE / June 29, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Biomea Fusion, Inc.. ("Biomea" or "the Company") (NASDAQ:BMEA) violations of the securities laws.

The Schall Law Firm Is Starting An Inquiry Into Accusations Against Biomea Fusion Inc And Invites Shareholders With Losses To Get In Touch

LOS ANGELES, CA / ACCESSWIRE / June 28, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Biomea Fusion, Inc.. ("Biomea" or "the Company") (NASDAQ:BMEA) violations of the securities laws.

The Schall Law Firm Is Starting A Probe Into Claims Against Biomea Fusion Inc And Invites Shareholders Who Have Suffered Losses To Contact Them

LOS ANGELES, CA / ACCESSWIRE / June 27, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Biomea Fusion, Inc.. ("Biomea" or "the Company") (NASDAQ:BMEA) violations of the securities laws.

The Schall Law Firm Begins A Probe Into Claims Against Biomea Fusion Inc And Urges Shareholders Who Have Suffered Losses To Contact

LOS ANGELES, CA / ACCESSWIRE / June 26, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Biomea Fusion, Inc.. ("Biomea" or "the Company") (NASDAQ:BMEA) violations of the securities laws.

The Schall Law Firm Is Initiating An Investigation Into Allegations Against Biomea Fusion Inc And Encourages Shareholders With Losses To Reach Out

NEW YORK , June 24, 2024 /PRNewswire/ -- Rosen Law Firm, a global investor rights law firm, announces an investigation of potential securities claims on behalf of shareholders of Biomea Fusion, Inc. (NASDAQ: BMEA) resulting from allegations that Biomea Fusion may have issued materially misleading business information to the investing public. So what: If you purchased Biomea Fusion securities you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fee arrangement.

BMEA Investors Have Opportunity to Lead Biomea Fusion, Inc. Securities Fraud Lawsuit

LOS ANGELES, CA / ACCESSWIRE / June 24, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Biomea Fusion, Inc.. ("Biomea" or "the Company") (NASDAQ:BMEA) violations of the securities laws.

Initiating An Investigation Into Allegations Against Biomea Fusion Inc The Schall Law Firm Invites Shareholders With Losses To Reach Out

LOS ANGELES, CA / ACCESSWIRE / June 23, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Biomea Fusion, Inc.. ("Biomea" or "the Company") (NASDAQ:BMEA) violations of the securities laws.

Commencing A Probe Into Accusations Against Biomea Fusion Inc The Schall Law Firm Encourages Shareholders With Losses To Connect

NEW YORK, NY / ACCESSWIRE / June 23, 2024 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Biomea Fusion, Inc. ("Biomea" or "the Company") (NASDAQ:BMEA). Investors who purchased Biomea securities are encouraged to obtain additional information and assist the investigation by visiting the firm's site: bgandg.com/BMEA.

Biomea Fusion, Inc. (BMEA) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Investors to Seek Compensation for Alleged Wrongdoings

LOS ANGELES, CA / ACCESSWIRE / June 22, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Biomea Fusion, Inc.. ("Biomea" or "the Company") (NASDAQ:BMEA) violations of the securities laws.

Beginning An Investigation Into Allegations Against Biomea Fusion Inc The Schall Law Firm Invites Shareholders With Losses To Reach Out

LOS ANGELES, CA / ACCESSWIRE / June 21, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Biomea Fusion, Inc.. ("Biomea" or "the Company") (NASDAQ:BMEA) violations of the securities laws.

Starting A Probe Into Claims Against Biomea Fusion Inc The Schall Law Firm Calls On Shareholders With Losses To Connect

NEW YORK, June 20, 2024 (GLOBE NEWSWIRE) -- Why: Rosen Law Firm, a global investor rights law firm, announces an investigation of potential securities claims on behalf of shareholders of Biomea Fusion, Inc. (NASDAQ: BMEA) resulting from allegations that Biomea Fusion may have issued materially misleading business information to the investing public.

Rosen Law Firm Encourages Biomea Fusion, Inc. Investors With Losses in Excess of $100K to Inquire About Securities Class Action Investigation – BMEA

LOS ANGELES, CA / ACCESSWIRE / June 19, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Biomea Fusion, Inc.. ("Biomea" or "the Company") (NASDAQ:BMEA) violations of the securities laws.

Starting A Probe Into Claims Against Biomea Fusion Inc The Schall Law Firm Welcomes Investors With Losses To Make Contact

LOS ANGELES, CA / ACCESSWIRE / June 18, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Biomea Fusion, Inc.. ("Biomea" or "the Company") (NASDAQ:BMEA) violations of the securities laws.

Schall Law Firm Initiates Investigation Into Allegations Against Biomea Fusion Inc And Urges Affected Investors To Get In Touch

LOS ANGELES, CA / ACCESSWIRE / June 17, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Biomea Fusion, Inc.. ("Biomea" or "the Company") (NASDAQ:BMEA) violations of the securities laws.

The Schall Law Firm Declares Investigation Into Allegations Against Biomea Fusion, Inc. And Urges Investors With Losses To Reach Out To The Firm

LOS ANGELES, CA / ACCESSWIRE / June 12, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Biomea Fusion, Inc.. ("Biomea" or "the Company") (NASDAQ:BMEA) violations of the securities laws.

Initiating An Investigation Into Allegations Against Biomea Fusion, Inc., The Schall Law Firm Invites Investors With Losses To Reach Out To The Firm

LOS ANGELES, CA / ACCESSWIRE / June 11, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Biomea Fusion, Inc.. ("Biomea" or "the Company") (NASDAQ:BMEA) violations of the securities laws.

The Schall Law Firm Announces Probe Into Claims Against Biomea Fusion, Inc. And Encourages Investors With Losses To Contact The Firm

Cleveland-Cliffs

NexPoint Strategic Opportunities Fund

PowerSchool Holdings

Squarespace

Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades, downgrades and initiations, please see our analyst ratings page.

This Cleveland-Cliffs Analyst Is No Longer Bullish; Here Are Top 5 Downgrades For Tuesday

LOS ANGELES, CA / ACCESSWIRE / June 9, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Biomea Fusion, Inc.. ("Biomea" or "the Company") (NASDAQ:BMEA) violations of the securities laws.

The Schall Law Firm Initiates Investigation into Accusations Against Biomea Fusion, Inc. and Urges Investors Suffering Losses to Liaise with the Firm

LOS ANGELES, CA / ACCESSWIRE / June 8, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Biomea Fusion, Inc.. ("Biomea" or "the Company") (NASDAQ:BMEA) violations of the securities laws.

The Schall Law Firm Announces Inquiry into Claims Against Biomea Fusion, Inc. and Encourages Investors with Losses to Contact the Firm

LOS ANGELES, CA / ACCESSWIRE / June 7, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Biomea Fusion, Inc.. ("Biomea" or "the Company") (NASDAQ:BMEA) violations of the securities laws.

The Schall Law Firm Declares Investigation into Allegations Against Biomea Fusion, Inc. and Invites Investors with Losses to Reach Out to the Firm

Biomea stock crashed Friday after the FDA placed two of the company's diabetes treatment studies on hold, citing concerns of liver toxicity.

Biomea Fusion Crashes 65% After FDA Puts Diabetes Treatment Studies On Hold

Biomea Fusion (NASDAQ: BMEA ) stock is falling hard on Friday after announcing a clinical hold has been put on its Phase I/II clinical trials of BMF-219. This clinical hold comes from the Food and Drug Administration (FDA) and has to do with safety concerns.

News for Biomea Fusion Inc Stock (BMEA)